Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (TRVI): 5 pipeline candidates · 2 upcoming catalysts · ~30 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
29.7 months
D/E 0.04 · 13% dilution
Lead: Phase 2/Phase 3
5 candidates
2 upcoming, next in ~196d
N/A
A transparent, data-derived signal for Trevi Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.1B
Cash
$19.4M
Quarterly Burn
$16.7M
Runway
29.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| haduvio | Phase 2/Phase 3 |
| nal er | Phase 2 |
| nalbuphine er | Phase 2/Phase 3 |
| nalbuphine hcl er | Phase 2/Phase 3 |
| nintedanib | Phase 1 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
197
Total value held
$1.32B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 10,240,186 | $122.2M |
| vanguard capital management llc | 9,957,134 | $118.8M |
| fmr llc | 8,038,061 | $95.9M |
| wellington management group llp | 5,189,088 | $61.9M |
| marshall wace, llp | 3,966,019 | $47.3M |
| mpm bioimpact llc | 3,298,430 | $39.4M |
| viking global investors lp | 3,198,644 | $38.2M |
| alliancebernstein l.p. | 2,845,472 | $35.6M |
| geode capital management, llc | 2,778,231 | $33.2M |
| state street corp | 2,665,313 | $31.8M |
Showing top 10 of 197 institutional holders of Trevi Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Trevi Therapeutics, Inc.'s pipeline?
Trevi Therapeutics, Inc. (TRVI) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Trevi Therapeutics, Inc.'s lead drug candidate?
Trevi Therapeutics, Inc.'s most advanced tracked candidate is haduvio (Phase 2/Phase 3) for Prurigo nodularis.
What is Trevi Therapeutics, Inc.'s next catalyst?
Trevi Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: haduvio" — expected December 31, 2026.
What is Trevi Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Trevi Therapeutics, Inc. has approximately 29.7 months of cash runway.
What is Trevi Therapeutics, Inc.'s market capitalization?
Trevi Therapeutics, Inc.'s market capitalization is approximately $2.1B.
Get the full picture on Trevi Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.